US 12,133,899 B2
Coronavirus vaccine
Ugur Sahin, Mainz (DE); Alptekin Güler, Mainz (DE); Andreas Kuhn, Mainz (DE); Alexander Muik, Seeheim-Jugenheim (DE); Annette Vogel, Mainz (DE); Kerstin Walzer, Seeheim-Jugenheim (DE); Sonja Witzel, Bad Vilbel (DE); Stephanie Hein, Rüsselsheim (DE); and Özlem Türeci, Mainz (DE)
Assigned to BioNTech SE, Mainz (DE)
Filed by BioNTech SE, Mainz (DE)
Filed on Nov. 16, 2022, as Appl. No. 17/988,742.
Application 17/988,742 is a continuation of application No. 17/233,396, filed on Apr. 16, 2021, granted, now 11,547,673.
Claims priority of application No. PCT/EP2020/061239 (WO), filed on Apr. 22, 2020; application No. PCT/EP2020/066968 (WO), filed on Jun. 18, 2020; application No. PCT/EP2020/068174 (WO), filed on Jun. 26, 2020; application No. PCT/EP2020/069805 (WO), filed on Jul. 13, 2020; application No. PCT/EP2020/071733 (WO), filed on Jul. 31, 2020; application No. PCT/EP2020/071839 (WO), filed on Aug. 3, 2020; application No. PCT/EP2020/073668 (WO), filed on Aug. 24, 2020; application No. PCT/EP2020/081544 (WO), filed on Nov. 9, 2020; application No. PCT/EP2020/081981 (WO), filed on Nov. 12, 2020; application No. PCT/EP2020/082601 (WO), filed on Nov. 18, 2020; application No. PCT/EP2020/082989 (WO), filed on Nov. 20, 2020; application No. PCT/EP2020/083435 (WO), filed on Nov. 25, 2020; application No. PCT/EP2020/084342 (WO), filed on Dec. 2, 2020; application No. PCT/EP2020/085145 (WO), filed on Dec. 8, 2020; application No. PCT/EP2020/085653 (WO), filed on Dec. 10, 2020; application No. PCT/EP2020/087844 (WO), filed on Dec. 23, 2020; application No. PCT/EP2021/050027 (WO), filed on Jan. 4, 2021; application No. PCT/EP2021/050874 (WO), filed on Jan. 15, 2021; application No. PCT/EP2021/050875 (WO), filed on Jan. 15, 2021; application No. PCT/EP2021/051772 (WO), filed on Jan. 26, 2021; application No. PCT/EP2021/052572 (WO), filed on Feb. 3, 2021; application No. PCT/EP2021/052716 (WO), filed on Feb. 4, 2021; and application No. PCT/EP2021/054622 (WO), filed on Feb. 24, 2021.
Prior Publication US 2024/0075165 A1, Mar. 7, 2024
Int. Cl. A61K 48/00 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); A61K 31/7088 (2006.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 31/7115 (2006.01); A61K 31/712 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/215 (2006.01); A61P 31/14 (2006.01); A61P 35/00 (2006.01); B82Y 5/00 (2011.01); C12N 7/00 (2006.01); C12N 15/11 (2006.01); C12N 15/67 (2006.01); C12N 15/88 (2006.01); C12P 19/34 (2006.01); A61K 38/00 (2006.01)
CPC A61K 48/0066 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1271 (2013.01); A61K 9/5123 (2013.01); A61K 9/5146 (2013.01); A61K 31/7088 (2013.01); A61K 31/7105 (2013.01); A61K 31/711 (2013.01); A61K 31/7115 (2013.01); A61K 31/712 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/215 (2013.01); A61K 48/0033 (2013.01); A61P 31/14 (2018.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01); C12N 7/00 (2013.01); C12N 15/11 (2013.01); C12N 15/67 (2013.01); C12N 15/88 (2013.01); C12P 19/34 (2013.01); A61K 38/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); C12N 2770/18022 (2013.01); C12N 2770/18034 (2013.01); C12N 2770/18071 (2013.01); C12N 2770/20034 (2013.01); C12N 2840/00 (2013.01)] 24 Claims
 
1. A pharmaceutical composition comprising an RNA that:
(i) includes modified uridines in place of all uridines, and
(ii) comprises a nucleotide sequence that encodes a polypeptide, wherein the polypeptide comprises:
(a) one or more fragments of a SARS-CoV-2 Spike (S) protein, wherein one of the fragments comprises a receptor binding domain (RBD),
(b) a secretory signal; and
(c) one or more additional domains selected from a trimerization domain, a transmembrane domain, and a combination thereof;
wherein the RBD is linked to one of the additional domains via a linker, and wherein the linker comprises a GS linker.